Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association (AHA) Scientific Sessions 2015

Business Wire November 6, 2015

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application for Opdivo (nivolumab) in Previously Treated Advanced Renal Cell Carcinoma

Business Wire November 5, 2015

Bristol-Myers Squibb to Present Data from 24 Abstracts in Immunoscience at the American College of Rheumatology (ACR) 2015 Congress

Business Wire November 5, 2015

Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program

Business Wire November 3, 2015

Bristol-Myers Squibb to Present at Credit Suisse 2015 Health Care Conference

Business Wire November 3, 2015

Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc.

Business Wire November 2, 2015

Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully Resected Stage III Melanoma

Business Wire October 28, 2015

Bristol-Myers Squibb's Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product

Business Wire October 28, 2015

Bristol-Myers Squibb Reports Third Quarter Financial Results

Business Wire October 27, 2015

Complete Phase 2a Study of HIV-1 Investigational Maturation Inhibitor Demonstrates Positive Results for Therapy Designed to Attack Virus Differently Than Existing Treatments

Business Wire October 23, 2015

Bristol-Myers Squibb to Present Data from Multiple Studies of Difficult-to-Treat Chronic Hepatitis C Patients at AASLD

Business Wire October 21, 2015

NICE Recommends Daklinza (daclatasvir) for Treatment of Certain Patients with Chronic Hepatitis C Genotypes 1, 3 and 4

Business Wire October 15, 2015

Bristol-Myers Squibb Appoints Paul Biondi Senior Vice President, Head of Business Development

Business Wire October 15, 2015

Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program

GlobeNewswire October 15, 2015

Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program

Business Wire October 15, 2015

Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy Fund

Benzinga.com  October 14, 2015

Bristol-Myers Squibb's Ready. Raise. Rise.(TM) Recognizes 23 Cancer Advocacy Groups in Immuno-Oncology Research Awareness Campaign

Business Wire October 13, 2015

Bristol-Myers Squibb's Opdivo (nivolumab) Receives Expanded FDA Approval in Previously-Treated Metastatic Non-Small Cell Lung Cancer (NSCLC), Offering Improved Survival to More Patients

Business Wire October 9, 2015

The Daily Screed: It’s starting to look like it doesn’t pay to be an ass

Chris Parry October 7, 2015

Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Second-line Hodgkin Lymphoma

Business Wire October 7, 2015